Sustainability | September 17, 2024
Piramal Pharma's GHG Commitment Validated and Approved by SBTi
This validation aligns with Piramal Pharma's core purpose of 'Doing Well and Doing Good,'
This validation aligns with Piramal Pharma's core purpose of 'Doing Well and Doing Good,'
Investment in new plant meets increasing demand for functional excipients for oral drug delivery
The new bioeconomy policy rolled out by the Modi government is set to place India as a global leader in the years to come
Q1 Consolidated operating profit Up 8.3%; revenue grows 7% to Rs 3,349 crore
Finance Minister Nirmala Sitharaman is set to present the full budget for the current financial year on July 23
Accelerating sustainability in Indian pharma industry
Launch of 20 new medicines expected by 2030
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
This partnership marks a significant step for the Company towards establishing renewable energy power generation using hybrid open excess through solar and wind sources
Subscribe To Our Newsletter & Stay Updated
